Claim Ownership

Author:

Subscribed: 0Played: 0
Share

Description

 Episodes
Reverse
Professor David Nutt is an English neuropsychopharmacologist specialising in the research of drugs that affect the brain.In this episode:The Endocannabinoid SystemTHC, CBD and other cannabinoidsCB1 and CB2 receptorsThe Entourage EffectConstituents of cannabisMedicinal CannabisSupport the podcast:Support the podcastSupport Mind Medicine Australia's mission:Mind Medicine AustraliaSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Dr James Fadiman is an American psychologist and writer. Fadiman received a Master's degree and a doctorate in Psychology from Stanford University back in 1960. His friend and former Harvard undergraduate advisor, Ram Dass (then known as Richard Alpert), introduced him to psychedelics. Fast-forward 60 years and Fadiman is now known and acknowledged for his research and clinical work in psychedelic therapy and microdosing. In this episode:Microdosing: Practice & BenefitsPsychedelics in psychiatryPsychedelics in optimisationHow psychedelics open up the capacity for changeSelf & SelvesSupport the podcast:Support the podcastSupport Mind Medicine Australia's mission:Mind Medicine AustraliaSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Katrin Preller received her PhD in Psychology and Neuroscience from University of Zurich, Switzerland in 2013. After completing her PhD, she investigated the effects of psychedelics on self-perception and social cognition. Her research interests are centred around the neuropharmacology of emotional and cognitive processes in health and psychiatric illnesses, as well as (pharmacological) neuroimaging analysis methodology. She is particularly interred in substance use disorders as well as the role of the serotonin system in emotion and cognition. She uses psilocybin and LSD to elucidate the role of 5-HT2A/1A receptor functions in human cognition.In this episode:Ingestion, absorption, and receptor activation of psilocybin and LSDBrain-wide changesWhy understanding mechanism will help therapy outcomesImplications for psychedelic therapySupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Professor Karl Friston is a British theoretical neuroscientist at University College London and an authority on brain imaging.Karl has been awarded with countless different prizes and accomplishments, and is considered one of the most influential neuroscientists of the modern era. He invented statistical parametric mapping (SPM), voxel-based morphometry (VBM) and dynamic causal modelling (DCM). Friston currently works on models of functional integration in the human brain and the principles that underlie neuronal interactions. His main contribution to theoretical neurobiology is a free-energy principle for action and perception (active inference). In this episode:Functional segregation, integration, and connectivityThe brain's generative modelThe brain's predictive model, prediction error and how to correct prediction errorFree energy principle and active inferencePsychopathology (false inference)How psychedelics alter the hierarchical architecture of the brainSerotonin, interoception, and 5HT2a agonismBrain-mind theoriesSelf-awareness in understanding mindSupport the podcast:Support the podcastSupport Mind Medicine Australia's mission:Mind Medicine AustraliaSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Dan Engle, MD, is a psychiatrist with a clinical practice that combines aspects of regenerative medicine, psychedelic research, integrative spirituality, and peak performance. Dan obtained his medical degree from the University of Texas at San Antonio. His psychiatry residency degree is from the University of Colorado Denver, and his child and adolescent psychiatry fellowship degree is from Oregon Health & Science University. Dr. Engle is an international consultant to several global healing centers facilitating the use of long-standing indigenous plant medicines for healing and awakening. He is the Founder and Medical Director of Kuya Institute for Transformational Medicine in Austin, Texas; Full Spectrum Medicine, a psychedelic integration and educational platform; and Thank You Life, a non-profit funding stream supporting access to psychedelic therapies. Dr. Engle is the author of The Concussion Repair Manual: A Practical Guide to Recovering from Traumatic Brain Injuries, as well as his more recent new book, A Dose of Hope: A Story of MDMA-Assisted Psychotherapy.In this episode:Transformational Medicine - 'hardware and software'A Dose Of HopeThe Power Of StorytellingSelf-Compassion, Self-Worth, and Self-ValueTrauma - Implications, Expressions, and SubjectivityTruths - Objective and SubjectiveMDMA - Psychology and BiologyActivating Your Innate Inner Healing IntelligenceThe Future of Psychiatric CareLinks:A Dose Of HopeDr Dan Engle's WebsiteFull Spectrum MedicineKuya Institute for Transformational MedicineThank You LifeSupport the podcast:Support the podcast (Patreon)Support Mind Medicine Australia's mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Lynn-Marie Morski, MD, JD is the president of the Psychedelic Medicine Association, host of the Plant Medicine Podcast, founder of Plant Medicine.org, and the medical director for Way of Leaf.com. Lynn-Marie is a Mayo Clinic-trained physician in family medicine and sports medicine, as well as an attorney and former adjunct law professor. She started the Plant Medicine Podcast to bring scientific researchers, practitioners, and those who have been personally affected by the healing powers of these plants together to help educate the public on what is possible and help further research and decriminalization of these substances. She later founded The Psychedelic Medicine Association; a society of physicians, therapists, and health care professionals looking to advance their education on the therapeutic uses of psychedelic medicines.The Psychedelic Medicine Association (PMA) is a public benefit corporation of healthcare providers aimed at bridging the gap between the advances taking place in the psychedelic research world and medical practitioners.In this episode:Factors that influence which psychedelic medicine is best suited for the patientLynn-marie’s therapeutic realisation Fundamentals of Psychedelic MedicineCommon myths or confusions in psychedelic medicineCurrent accessibility Western and indigenous perspectives of illness and wellness4 big hurdles preventing doctors prescribing psychedelicsHow to approach stigma within the health-care communityHarm reductionLinks:Psychedelic Medicine AssociationPlant Medicine Podcast (Spotify)PlantMedicine.orgSupport the podcast:Support the podcast (Patreon)Support Mind Medicine Australia's mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Adam Gazzaley MD, PhD is a neuroscientist, neurologist, inventor, author, photographer, entrepreneur and investor.Adam obtained an M.D. and a Ph.D. in Neuroscience at the Mount Sinai School of Medicine in New York, completed Neurology residency at the University of Pennsylvania, and postdoctoral training in cognitive neuroscience at University of California, Berkeley. He is now the David Dolby Distinguished Professor in Neurology, Physiology and Psychiatry at University of California, San Francisco and the Founder / Executive Director of Neuroscape, a translational neuroscience center engaged in technology creation and scientific research.In this episode:Humans as information seeking creaturesHow technology has challenged our brainBottom-up and top-down attentionAdvancing psychedelic researchThe role of context in experience outcomesThe mind as a functional product of the brainNeuroplasticity (experience-dependent plasticity and self-directed plasticity)Creating an interpretable real-time experience landscapePsychedelics in neurodegenerative illnessLinks:NeuroscapeAdam GazzaleySupport the podcast:Support the podcast (Patreon)Support the mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Prof David Nutt is Neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep. David is the chairman of Drug Science, a non-profit which he founded in 2010 to provide independent, evidence-based information on drugs. Nutt is the deputy head of the Centre for Psychedelic Research at Imperial College London. He and his team have published research into psilocybin for TRD, as well as neuroimaging studies investigating psilocybin, MDMA, LSD, and DMT.In this episode:How drugs help our understanding of the brainImpact of prohibition on investigation and researchKey terms - decriminalisation, depenalisation, legalisationDrug harm profiles - alcohol, lsd, mdma, psilocybinPhysiology and psychology of addictionBrain-mind interplayThe psychedelic experience and its phenomena The default mode networkFunctional connectivityNeuroplasticityWhy profound alterations in consciousness permit long-term changesSerotonin's role in depressionPsilocybin vs SSRIs and the 5HT2a receptorPsychedelics vs Psychedelic-assisted psychotherapies Links:Drug ScienceThe Drug Science PodcastDavid Nutt on TwitterRecent paper exploring Psilocybin vs SSRIs:Serotonin and brain function: a tale of two receptorsSupport the podcast:Support the podcast (Patreon)Support the mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Dennis McKenna is an Ethnopharmacolgist, research pharmacist, lecturer, and author. Dennis is a founding member and director of ethnographic research at the Heffter Research Institute, a non-profit organization involved in investigating the potential of therapeutic use of drugs. He is the brother of the famous psychedelic advocate Terence McKenna.In this episode:Preserving indigenous practice, challenges we faceMckenna Academy of Natural PhilosophyThe brain as a reducing valve of realityThe mind-brain problemPsychedelics bring the background forwardSerotoninConsciousness and symbiosisWhat research questions should be asked in the next 5-10 yearsWho will be the gatekeepers of these medicinesThe need to arm psychiatrists and mental health practitioners with psychedelicsSupport the podcast:Support the podcast (Patreon)Support the mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Andrew Robb was Australia’s Minister for Trade, Investment, and Tourism. Currently, Andrew is the chairman of The Robb Group (corporate and investment advisory company) and is a board member for multiple organizations, including Mind Medicine Australia. He is the author of Black Dog Daze: Public Life, Private Demons, his memoir that explores the challenges of managing depression, political ambition, and the life of the liberal party. In this episode:Personal journey - political ambition, battles with depressionExperience with antidepressantsWhen his antidepressants stopped workingPsychedelic therapy remission statisticsApproving this type of therapy on the state and federal levelInforming and educating politicians Support the podcast:Support the podcast (Patreon)Support the mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Nigel Denning is the Director and Counselling Psychologist at Integrative Psychology Nigel is a former Family Violence Co-ordinator for Relationships Australia and is the Deputy President of the In Good Faith Foundation. He has studied in the United States and Europe with Dr. Stanislac Grof, one of the founders of Transpersonal Psychology and Holotropic Breathwork. He has also helped build and deliver the Certificate in Psychedelic-Assisted Therapies (CPAT), which has been developed primarily to meet the demand for trained therapists to provide regulatory approved and research-backed psychedelic-assisted therapies for the treatment.In this episode:Consciousness as a discussion in psychologyBio-psycho-social modelPsychedelic-assisted psychotherapyConnectionSelf-transcendenceLoveMeditationCPAT (Certificate in Psychedelic-Assisted Therapies)Links:CPATIntegrative PsychologySupport the podcast:Support the podcast (Patreon)Support the mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Lars Wilde is the President, Chief Business Officer, and Co-founder of COMPASS Pathways. COMPASS is a UK life sciences company that works to expedite the approval and delivery of mental health therapies to patients and focuses primarily on testing psilocybin for use in patients with treatment-resistant depression (TRD). They have 22 trials running through the US and Europe for TRD.In this episode:Personal journey and battles with anxiety, and seeking psychiatric helpThe subjective experience of psilocybin and impact of emotional processing and cognitive functionBirth of COMPASSThe current landscape of the researchModels for therapies and how they can scaleResearch questions that need to be addressedCOMPASS decision to patent psilocybin (and what this means for its scientific exploration)Rescheduling psilocybinLinks:COMPASS PathwaysSupport the podcast:Support the podcast (Patreon)Support the mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
David Bryce Yaden, Ph.D. is a Postdoctoral Research Fellow at Johns Hopkins Medicine in The Center for Psychedelic and Consciousness Research. David's research focus is on the psychology, cognitive neuroscience, and psychopharmacology of spiritual, self-transcendent, and positively transformative experiences triggered with psychedelic substances and other means. Specifically, he is interested in understanding how these experiences can result in long-term changes to well-being and how they temporarily alter fundamental faculties of consciousness such as the sense of time, space, and self.He is the editor of Rituals and Practices in World Religions: Cross-Cultural Scholarship to Inform Research and Clinical Contexts. He is currently writing a book called The Varieties of Spiritual Experiences: A Twenty-First Century Update for Oxford University Press. His scientific and scholarly work has been covered by The New York Times, The Wall Street Journal, The Washington Post, New York Magazine, and NPR.In this episode:Self-transcendent experience that lead him to this spaceAttempting to understand the brain and mind in these experiencesLeveraging neuroimaging to describe self-transcendence Cautioning neuroimaging to define the psychedelic experienceProspection and the idea of being pulled into the futureSelflessness vs. feelings of connectionTime, space, and selfPsychedelic research entering maturityThe need to arm psychiatrists with psilocybinLinks:David B. Yaden on TwitterPsychedelics in Psychiatry - Keeping the Renaissance From Going Off the RailsSupport the podcast:Support the podcast (Patreon)Support the mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Dr. Rachel Yehuda, PhD. is a Professor of Psychiatry and Neuroscience, and Director of the Center for Psychedelic Psychotherapy and Trauma Research at Mount Sinai School of Medicine in New York. This research includes the PTSD clinical research program and the Neurochemistry and Neuroendocrinology laboratory at the James J. Peters Veterans Affairs Medical Centre.In this episode:Defining traumaDiagnosing post-traumatic stress disorder (PTSD)Symptomatology associated with trauma and PTSDThe stress response, including brain regions associated with memoryCurrent treatments Psychedelic-assisted therapies, including MDMA-assisted psychotherapySupport the podcast:Support the podcast (Patreon)Support the mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
The scope of psychedelic research is expanding and it's only in the last couple of decades that we have been able to find how MDMA, among other psychedelic compounds, exert their effect in the body. Pharmacology is the use, effects, and modes of drug action. In this episode:Pharmacology and therapeutic mechanisms of MDMA:Where does psilocybin exert its effect in our body?How is it metabolised?What receptors in the brain and body does it engage with?What is the result of the change in physiology?Support the podcast:Support the podcast (Patreon)Support the mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
The scope of psychedelic research is expanding and it's only in the last couple of decades that we have been able to find how psilocybin, as well as other psychedelic compounds, exert their effect in the body. Pharmacology is the use, effects, and modes of drug action.In this episode:Pharmacology and therapeutic mechanisms of Psilocybin:Where does psilocybin exert its effect in our body?How is it metabolised?What receptors in the brain and body does it engage with?What is the result of the change in physiology?Support the podcast:Support the podcast (Patreon)Support the mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Peter Hunt AM is a Social Entrepreneur, Investor and Engaged Philanthropist, Founder Greenhill Australia, Women's Commnity Shelters and Mind Medicine Australia.In this episode:Stats on mental illness in AustraliaPsilocybin and MDMA - psychological phenomena and scientific evidenceAntidepressants / SSRIs and common pharmaceutical treatmentsReinforcement of mental illness through diagnosisDestigmatizing drugs and the word "drug"The context of psychedelic psychotherapy including its set and settingHow drug legislation worksSupport the podcast:Support the podcast (Patreon)Support the mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Rick Doblin, PhD. is the founder and executive director of the Multidisciplinary Association of Psychedelic Studies (MAPS).MAPS is a non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.Rick did his Master's thesis on a survey of oncologists on cannabis in nausea control for cancer patients. He received his doctorate in Public Policy from Harvard's Kennedy School of Government, where he wrote his dissertation on regulating medical uses for psychedelics and cannabis.In this episode:MAPS' missionMDMA history, stigma, and backlashCommon myths of the pharmacology of MDMATherapeutic use in therapyFear extinction and memory reconsolidationDrug reschedulingCurrent and emerging researchLinks:MAPS (Multidisciplinary Association of Psychedelic Studies)Support the podcast:Support the podcast (Patreon)Support the mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Reid Robison, MD MBA, is a psychedelic psychiatrist & researcher.Reid has led over 100 clinical trials in neuropsychiatry. He completed his undergraduate in Neuroscience at Brigham Young University and went on to medical school at the University of Utah where he earned both his MD and MBA. Of course, he didn’t stop there, after residency training in Psychiatry, Dr Robison completed fellowship training in Neurodevelopmental Genetics, followed by a postdoc in Bioinformatics. As an early adopter and researcher of Ketamine in psychiatry, Reid obtained his first grant to study ketamine in 2011. He also led the Utah site for the pivotal ketamine study for TRMDD by Janssen, leading up to the company’s recent FDA-approval of Spravato. To date, Reid has guided thousands of ketamine therapy journeys and hundreds of Spravato dosing sessions. Reid has built a number of therapeutic-driven companies including Tute Genomics, a venture-backed personalized medicine startup that was acquired in 2016, Cedar Psychiatry, which he co founded and serves as a Medical Director of Center for Change, a top Eating Disorder program. He is also a founding board member at the Utah-based non-profit organisation Psychedelic Institute. Reid is adjunct faculty at the University of Utah, founder of the Polizzi Free Clinic, and provides medical support and psychedelic therapy at plant medicine retreats abroad, and is the coordinating investigator for the MAPS MDMA-assisted Psychotherapy study of Eating Disorders.In this episode:Mental health crisisEpigenetics and genetics in mental health conditionsResetting and opening up new neural pathwaysNeuroscience of ketaminePharmacogeneticsLinks:NovamindCedar PsychiatrySupport the podcast:Support the podcast (Patreon)Support the mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Dr Tanveer Ahmed is a psychiatrist, author and columnist. Tanveer works in the public, private and forensic sectors. He has served on local government, the government advisory body called the Australia Multicultural Council, the Advertising Standards Board and as a Governor of the Smith Family. His 2 books Fragile Nation and In Defence Of Shame examine the rise of mental health conditions and explore the complexity of mental distress. He was previously chosen by a Prime Minister's committee as one of a hundred future leaders of Australia.Topics covered:The balance of health and economics in a pandemicThe medicalisation of experienceThe 3 disciplines of mental healthThe primitive "lizard" brainUnending novelty exploiting primitive circuitsModern masculinityPsychedelic therapies "Shaking up" rigid circuits with psychedelic therapySupport the podcast:Support the podcast (Patreon)Support the mission:Mind Medicine AustraliaDonate to Mind Medicine AustraliaJoin a local chapterSupport this show http://supporter.acast.com/mind-medicine-australia. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.
Comments 
Download from Google Play
Download from App Store